A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4622191
Author(s) Huynh, Christine; Henrich, Andrea; Strasser, Daniel S.; Boof, Marie-Laure; Al-Ibrahim, Mohamed; Meyer Zu Schwabedissen, Henriette E.; Dingemanse, Jasper; Ufer, Mike
Author(s) at UniBasel Meyer zu Schwabedissen, Henriette
Huynh, Christine
Year 2021
Title A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker
Journal Clinical Pharmacology and Therapeutics
Volume 109
Number 6
Pages / Article-Number 1648-1659
Abstract The C-X-C chemokine receptor 7 (CXCR7) has evolved as a promising, druggable target mainly in the immunology and oncology fields modulating plasma concentrations of its ligands CXCL11 and CXCL12 through receptor-mediated internalization. This "scavenging" activity creates concentration gradients of these ligands between blood vessels and tissues that drive directional cell migration. This randomized, double-blind, placebo-controlled first-in-human study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACT-1004-1239, a first-in-class drug candidate small-molecule CXCR7 antagonist. Food effect and absolute bioavailability assessments were also integrated in this multipurpose study. Healthy male subjects received single ascending oral doses of ACT-1004-1239 (n = 36) or placebo (n = 12). At each of six dose levels (1-200 mg), repeated blood sampling was done over 144 hours for pharmacokinetic/pharmacodynamic assessments using CXCL11 and CXCL12 as biomarkers of target engagement. ACT-1004-1239 was safe and well tolerated up to the highest tested dose of 200 mg. CXCL12 plasma concentrations dose-dependently increased and more than doubled compared with baseline, indicating target engagement, whereas CXCL11 concentrations remained unchanged. An indirect-response pharmacokinetic/pharmacodynamic model well described the relationship between ACT-1004-1239 and CXCL12 concentrations across the full dose range, supporting once-daily dosing for future clinical studies. At doses ≥ 10 mg, time to reach maximum plasma concentration ranged from 1.3 to 3.0 hours and terminal elimination half-life from 17.8 to 23.6 hours. The exposure increase across the dose range was essentially dose-proportional and no relevant food effect on pharmacokinetics was determined. The absolute bioavailability was 53.0% based on radioactivity data after oral vs. intravenous; 14; C-radiolabeled microtracer administration of ACT-1004-1239. Overall, these comprehensive data support further clinical development of ACT-1004-1239.
Publisher Wiley
ISSN/ISBN 0009-9236 ; 1532-6535
edoc-URL https://edoc.unibas.ch/83965/
Full Text on edoc No
Digital Object Identifier DOI 10.1002/cpt.2154
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/33406277
ISI-Number WOS:000617932000001
Document type (ISI) Article
 
   

MCSS v5.8 PRO. 0.287 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
07/12/2022